THE PRESENT AND FUTURE

JACC STATE-OF-THE-ART REVIEW

Machine Learning and the Future of Cardiovascular Care

JACC State-of-the-Art Review

Giorgio Quer, PHD,[a] Ramy Arnaout, MD, DPHIL,[b] Michael Henne, MPH,[c] Rima Arnaout, MD[d]

ABSTRACT

The role of physicians has always been to synthesize the data available to them to identify diagnostic patterns that guide treatment and follow response. Today, increasingly sophisticated machine learning algorithms may grow to support clinical experts in some of these tasks. Machine learning has the potential to benefit patients and cardiologists, but only if clinicians take an active role in bringing these new algorithms into practice. The aim of this review is to introduce clinicians who are not data science experts to key concepts in machine learning that will allow them to better understand the field and evaluate new literature and developments. The current published data in machine learning for cardiovascular disease is then summarized, using both a bibliometric survey, with code publicly available to enable similar analysis for any research topic of interest, and select case studies. Finally, several ways that clinicians can and must be involved in this emerging field are presented. (J Am Coll Cardiol 2021;77:300–13) © 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Machine learning (ML)—the use of computer algorithms that can learn complex patterns from data—has significant potential to affect cardiology due to the number of diagnostic and management decisions that rely on digitized, patient-specific information such as electrocardiograms (ECGs), echocardiograms, and more (1), and due to the growing amount and complexity of medical knowledge. The staggering volume of health care data—clinical notes, wearable and sensor data, medication lists, imaging, and much more—continues to increase astronomically, with 2 zettabytes (1 zettabyte = 1 trillion gigabytes) estimated to be produced in 2020 (2). Simply put, "the complexity of medicine now exceeds the capacity of the human mind" (3). As a result, our knowledge and interpretation of available data, our skills, and our practice may vary from clinician to clinician, sometimes failing to leverage all of medical knowledge. Designed, validated, and implemented appropriately, ML algorithms will help in acquiring, interpreting, and synthesizing health care data from disparate sources and putting it at our fingertips—as if we had an expert subspecialist to call upon for every patient and every clinical situation.

As ML algorithms permeate into clinical cardiology, they may be deployed in multiple areas. Algorithms may help the front office schedule different

Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.

<div style="border:1px solid">

HIGHLIGHTS

- ML algorithms can find sophisticated patterns in medical data and have the potential to improve cardiovascular care.

- Cardiologists must take an active role in shaping how ML is used in cardiovascular practice and research.

- To empower cardiologists in this role, we provide a framework to help critically evaluate developments in ML.

- We also provide an open-source bibliometric survey of ML in cardiology.

</div>

patients with the appropriate amount of time based on their electronic health record (EHR) data, or help primary care physicians better guide referrals to the cardiologist's office. ML will help in remote testing and monitoring of patients, guiding the data acquisition that will be sent to a clinic or hospital. Perhaps the computer-generated ECG reports will become more reliable, because ML algorithms are analyzing the signal. Ultrasound, nuclear, computed tomography (CT), and cardiac magnetic resonance (CMR) images will be better-protocolled and have less image noise or fewer artifacts. Automated cardiac measurements from echocardiograms, CT scans, and CMRs may become more accurate and reliable (4). Perhaps cardiac risk scores will not be calculated from just a handful of variables, but from every piece of data in the patient's chart. Perhaps ML algorithms will help us discover new and subtle patterns in data that may change how we care for our patients. Perhaps clinical guidelines may recommend ML-enabled testing for patient diagnosis and management. Taken together, these and other ML-based improvements may make for a revolution in cardiology. Despite this potential, and a growing body of literature (detailed in the following text), ML's real-world impact on clinical cardiologists and their patients has been quite limited to date (1,5).

To borrow from American poet and musician Gil Scott-Heron, this revolution will not be televised. By the time algorithms like those described in the previous text make it into the clinic, their presence will be largely invisible to the practitioner. Cardiologists' active involvement in ML *before* it reaches the clinic is critical to help it reach its full potential for patient care. Cardiologists will be the ones to follow new developments in medical ML, serve as peer reviewers, and evaluate whether new work is impactful or incremental to patients and providers. Cardiologists

will lead clinical trials evaluating efficacy and safety of ML algorithms, just as they do for drugs or medical devices. In the clinic, cardiologists will help decide, for example, whether to buy new ML-powered software to improve clinical operations or diagnosis. When an ML algorithm suggests an unusual result, cardiologists will have to decide whether that result is spurious or a truly novel finding that a physician would not see on his or her own. And they will have to explain their reliance on or rejection of ML-based test results to their patients. For all of these reasons, even cardiologists who are not ML experts can benefit from some basic tools and concepts with which to understand, evaluate, and, when appropriate, champion the incorporation of evidence-based ML research into their practice.

The goal of this review is to present these concepts for ML, to provide a way to survey the ever-growing body of literature in ML for cardiology, and to provide suggestions for how cardiologists who are not data science experts can participate in the ML revolution.

ML: KEY CONCEPTS FOR BUSY CLINICIANS

In this section we will provide a brief overview of 6 ML concepts that clinicians need to be familiar with to read clinical papers using ML methods and, eventually, to facilitate the use of novel ML algorithms inside the clinic. Our goal is not to provide a comprehensive technical primer on ML algorithms, which is already well covered in several excellent resources (4-11).

Artificial intelligence (AI), simply defined as a computer system that is able to perform tasks that normally require human intelligence, is something cardiologists have been taking advantage of for decades virtually every day as hundreds of millions of ECGs are interpreted by computers worldwide every year (12,13). Here, we will use ECG analysis as a canonical example to illustrate several concepts in ML, because it is clinically familiar and has been well-studied by humans, non-ML computer algorithms, and ML algorithms alike.

CONCEPT 1. TRADITIONAL RULES-BASED ALGORITHMS APPLY RULES TO DATA, WHILE ML ALGORITHMS LEARN PATTERNS FROM DATA. Computers can mimic human intelligence through rules-based algorithms, used in traditional computerized ECG interpretation (12), or, through ML algorithms. Rules-based algorithms make use of a set of rules explicitly programmed by humans to mimic the knowledge a cardiologist might use in

reading the ECG, for example: determining the rate, identifying P waves before every QRS, and recognizing pathognomonic waveform changes. In this case, the rules used that lead to a computer's ECG diagnosis are well understood.

In contrast to rules-based algorithms, ML algorithms that learn rules and patterns from the data fed to them, rather than having those rules explicitly programmed. This fundamental difference is responsible for both the excitement about ML algorithms' potential to solve problems in cardiology beyond human capability—for example, detecting patients with ejection fraction ≤35% or detecting patients with hypoglycemia based on an ECG alone (14,15)—but it is also cause for the caution clinicians must have in evaluating and eventually implementing ML solutions.

There are several types of ML algorithms, from decision trees and support vector machines, to highly complex, data-hungry algorithms called neural networks. Neural networks are used in deep ML (deep learning), and their ability to analyze large amounts of highly complex data—EHR data, for example, or the collection of pixels that make up medical images—are especially exciting for cardiology applications. An ML algorithm is trained on data, yielding a trained ML *model* that can then be evaluated on never-before-seen test data. Several excellent reviews discuss different types of ML algorithms, including neural networks, in more detail (10,16-18).

CONCEPT 2. ML ALGORITHMS CAN LEARN PATTERNS FROM LABELED EXAMPLES: SUPERVISED LEARNING. ML algorithms can learn patterns from data in 2 main ways. The first approach is to provide data (e.g., a set of ECGs from patients visiting a clinic) along with a corresponding label for what the algorithm is meant to learn (in this example, the label would be the diagnosis for each single ECG). This approach is called supervised learning (14,19-21). Based on the labeled examples alone, the algorithm learns for itself the most important features of the ECG that drive its decision and devises rules to exploit those features for diagnosis of new ECGs never seen before.

Supervised learning algorithms have the advantage of having a clear goal: predicting the label of interest. But the disadvantage of supervised ML algorithms is that their ability to find interesting patterns in the data is also constrained by those labels. As any clinician who has written question-and-answers for board prep or put together a self-assessment program knows, choosing the right data for training and deciding on the correct answer or label is critically important to training and takes a lot of work.

Similarly, a major challenge in supervised ML is the availability of datasets of adequate size that have correctly annotated labels of interest. This is not always straightforward. For example, data scientists may trust that when a patient has a specific diagnostic code in their EHR, such as acute venous thromboembolism (VTE), that the diagnostic code can serve as an accurate clinical label for VTE. However, studies have founded that a VTE diagnosis in the EHR has a positive predictive value as low as 31% for an outpatient diagnosis and 65% for an inpatient diagnosis (22). Therefore, correct labelling of datasets requires active curation by physicians, and will often require consensus from more than 1 physician.

CONCEPT 3. ML ALGORITHMS CAN LEARN PATTERNS WITHOUT LABELED EXAMPLES: UNSUPERVISED AND REINFORCEMENT LEARNING. The second approach for learning that can be used is unsupervised learning, designed to discover the hidden patterns by analyzing data without a label. An unsupervised learning approach is similar to a medical student that is given a huge number of ECGs without any diagnosis. The student may not have been told what atrial fibrillation is or what a left bundle branch block looks like, or that pericarditis can cause PR segment depression, but he/she can still classify the examples in similar groups, selecting the most important ECG characteristics that he/she thinks differentiate one example from another. He/she may learn on his/her own that the bumps and squiggles in an ECG seem to follow a certain sequence and that they have different durations and morphologies, or he/she may notice an entirely novel characteristic not typically taught in the textbooks. In the same way, an algorithm can cluster available data in several groups, and can learn the data features that are most relevant in differentiating the examples.

Unsupervised learning holds several advantages in ML: it allows the algorithm to develop an understanding of the data that is unconstrained by labor-intensive and often variable human labels, and it allows the algorithm to come up with novel groupings and clusters of the data that a human being may not be aware of. These learned features as groupings can also be exploited by a subsequent supervised learning step (23), just as the medical student, having pre-digested the ECGs on his/her own, then has an easier time learning that certain patterns correspond to sinus arrhythmia or hyperkalemia.

Unsupervised learning approaches are common in the analysis of EHR or genetic data to automatically extract the most useful information (24) to identify distinct disease subgroups—of type 2 diabetes, for

| TABLE 1 Roles for the Non-ML Expert in Machine Learning for Cardiology |
| --- |
| Being an informed consumer of the literature and of cardiac ML research projects. |
| Collaborating with ML and data science experts to innovate clinical practice. |
| Beta-testing AI-enabled products in the clinical setting. |
| Advising one's medical center, clinic, or institution on investments in data science and ML tools. |
| Advocating for responsible data sharing at one's institution and via professional societies. |
| Advocating for harmonization and standardization of data formats and data processing across institutions. |
| Ensuring that algorithms have been trained from data that adequately represents patients, acquisition methods, and equipment, and other factors. |
| Participating in annotation of datasets as the clinical expert. |
| Participating in validating model predictions as the clinical expert. |
| Testing AI-enabled clinical products and/or novel insights in randomized controlled trials. |
| Evaluating and incorporating AI-based decision making in updated clinical guidelines documents. |
| Creating and promoting training opportunities (courses, fellowships) in data science for cardiology trainees and in clinical science for data scientists. |
| Evaluating and updating cardiology training—what core competencies will remain a requirement, and what will be replaced by ML? |
| AI = artificial intelligence; ML = machine learning. |

example (25)—or to find a new set of biomarkers that may be better predictors than standard biomarkers in defining distinct subsets of individuals with similar health status (26). Clustering—dividing any type of data in groups of similar datapoints based on the data's characteristics—is indeed a successful application of unsupervised learning to clinical data (27,28). As in the previous text, the clusters generated may lead to novel groups of datapoints that may illuminate novel subgroups of disease, new biomarkers, or new predictors of a clinical outcome of interest. However, clustering often represents only the first step to group the data before a more insightful analysis. Importantly, clusters that may suggest new groupings of disease or other novel insights must be validated clinically, as it can be easy to set clustering parameters to create subgroups, or lump together groups that should be separate.

In addition to supervised and unsupervised learning, a third category of learning methods, reinforcement learning, is used when the ML algorithm is given iterative information about the outcome of its predictions in the environment as feedback that helps guide its future predictions. Imagine training an ML algorithm to dose intravenous heparin, for example. For this task, neither a supervised approach, such as labeling different doses of heparin as "good" or "bad," nor an unsupervised approach (no label at all) would work well. Instead, in a reinforcement learning approach, the algorithm would have a goal—optimize

CENTRAL ILLUSTRATION Marked Growth in Cardiac AI/ML Studies Span Several Disease Focus Areas and Several Data Types

Quer, G. et al. J Am Coll Cardiol. 2021;77(3):300-13.

Publications on machine learning in cardiology continue to grow (**inset** shows cumulative number of cardiac artificial intelligence/machine learning papers). Several disease categories and data modalities have been studied in these publications, but several areas remain open for further exploration. *Partial information for the year 2020. AI = artificial intelligence; CT = computed tomography; ECG = electrocardiogram; EHR = electronic health record; ML = machine learning; MRI = magnetic resonance imaging; US = ultrasound.

FIGURE 1 Marked Growth in Cardiac AI/ML Studies

The plots show **(top)** numbers of publications per year, with **red** denoting original research, whereas **blue** denotes nonoriginal articles such as reviews and commentary; **(middle)** the total number of papers (any topic) added to each of the 3 collections; and **(bottom)** the percentage of papers on cardiac artificial intelligence (AI)/machine learning (ML). The **insets** for PubMed in the first 2 rows show the cumulative number of papers across all previous years, while in the third row it shows the cumulative percentages considering all papers until that year. *2020 numbers are partial.

partial thromboplastin time—and would predict different heparin doses, receiving a positive or negative reward depending on how close to the goal partial thromboplastin time it got. That reward would then inform the algorithm's next guess, and so forth. Reinforcement learning has been used with success to learn complex strategy games like Go (23), where the goals and the effect of the algorithm's decision on the environment is clear, and where the algorithm can play Go millions of times, often losing the game until it learns. It has also been studied for some clinical tasks, such as guiding dofetilide dosing or ventilator settings (29,30). However, reinforcement learning may be of limited use in clinical tasks where the goal and the environment's possible response are much more complex, and where "losing the game" in a clinical setting during the learning phase of the algorithm is not ethically acceptable.

CONCEPT 4. WHEN ML ALGORITHMS LEARN RULES THAT PERFORM WELL ON TRAINING DATA BUT FAIL ON TEST DATA, THEY HAVE FAILED TO LEARN RULES THAT ARE GENERALIZABLE. This problem, called overfitting, happens when there is mismatch between the complexity of the ML algorithm and the size of the training dataset provided to it. Take, for example, a very complex algorithm trained on a small dataset: the algorithm learns rules so tailored to the specific training examples at hand that it has in effect "memorized" them instead of learning the general rules behind them. This means the model performance will appear to be very good, but then fail when deployed on larger datasets. The problem is even more severe in the presence of class imbalance, that is, when 1 subgroup of the training data has only very few samples.

Overfitting is one of the most common problems encountered when using supervised ML algorithms, and the main limitation to their application to real-life clinical situations (31). Overfitting can happen to human learners as well, for example, the fellow who has studied 10 ECGs very closely but then fails the board examination. To date, however, a human learner is typically much better at generalizing knowledge from a small dataset than an ML algorithm.

It is common to estimate the complexity of an ML model based on the number of parameters in the trained model, which can be in the order of hundreds of millions for modern deep learning architectures,

**FIGURE 2** Content in Cardiac AI/ML Publications on PubMed

(A) Distribution of publications by disease category. (B) Distribution of publications by data modality. (C) Number of papers studying various cardiac disease categories by data type (waveform data includes catheterization, arterial pulse waveforms, plethysmography, and other waveform data but does not include ECG; atherosclerosis includes dyslipidemia, peripheral vascular disease and cerebrovascular disease). (D) Distribution of publications by goal. (E) Distribution of publications by machine learning method. CT = computed tomography; ECG = electrocardiogram; EHR = electronic health record; MRI = magnetic resonance imaging; SVM = support vector machine; US = ultrasound.

even when trained on just a few thousand training examples (32). Methods to mitigate overfitting include: 1) reducing the model complexity; 2) increasing the number of examples in the training set (although this is often not possible); 3) limiting the number of iterations of the algorithm (i.e., training cycles) on the training data; 4) balancing the parameters learned in the model (regularization) to obtain a simpler model that underfits on the training data but generalizes better; and 5) using not one model but an

FIGURE 3 An International and Collaborative Effort

(A) Total publications on cardiac artificial intelligence/machine learning in PubMed, worldwide, and in the United States (note log scale). **(B)** Publications per capita worldwide and in the United States (note log scale). **(C)** Collaborations measured by author locations on each publication, presented worldwide and statewide (for clarity, only top 10 countries and/or states are labeled).

ensemble of separate models to come to the desired prediction so that various overfitting effects of each singular model balance out (33).

Given the common and dangerous issue of overfitting, the performance of the trained model must be tested on cases that are completely independent from the training examples, and ideally, from test data from multiple external medical centers. To evaluate performance of any ML algorithm on a clinical task, full information on the data and methods used in training and testing must be reported (11).

CONCEPT 5. ACCURACY, INTERPRETABILITY, AND EXPLAINABILITY OF AN ML ALGORITHM. Simply put, diagnostic accuracy is defined by the proportion of correct predictions (true positives and true negatives) in a given test dataset. Supervised ML models can be more accurate on a given diagnostic task than the average clinician, as shown by deep learning algorithms matching the diagnostic accuracy of a team of 21 board-certified practicing cardiologists in the classification of 12 heart rhythm types from single-lead ECGs (19).

However accurate they may be, typically, the rules by which ML models have achieved their performance are not clear—this is especially true for highly complex neural networks. This lack of easy interpretability of the neural networks' decision-making means that it can be difficult to verify the learned rules have truly generalized to real-life clinical situations (34).

It can also be difficult to learn from novel features or patterns the ML algorithms may have detected. Lack of interpretability raises some important questions for the clinician.

First, does it matter that we do not know how a tool works, as long as we have validated that it works very well? Second, what is the level of testing an ML model must go through to be considered safe for clinical situations, especially when we do not know how it works?

Although one would like an ML model to maximize both accuracy and interpretability, to date there is a tradeoff between the 2, especially when using neural networks (deep learning), whose operations are often too complicated to analyze and interpret. As clinicians, we may need to choose whether to take advantage of a "black-box" algorithm with proven 99% accuracy, or an interpretable algorithm with recognizable features that lead to the model decision, but has only 80% accuracy (35). The debate on this topic is still open and it is one of the reasons for the slow adoption of current ML techniques in medicine. Possible solutions to this dilemma are the use of interpretable models substituting the black box algorithms (34), or the use of model-agnostic methods to

explain the decision of the black box with local (case-specific) and global (model-specific) explanations (36). Clinicians will need to evaluate algorithms in clinical trials and incorporate their recommendations in guidelines documents (**Table 1**). A more futuristic approach involves the redesign of AI models toward a knowledge-driven reasoning-based approach, which may be extremely valuable in medicine, but these methods are currently under investigation in the computer science world, while their applicability in medicine is likely at least a decade away (37).

CONCEPT 6. ML ALGORITHMS CAN BE RETRAINED TO INCLUDE MORE DATA OR DIFFERENT DATA TYPES.

Like a medical student can learn to interpret many different types of data—ECGs, chest X-rays, laboratory values—and, with proper training, can improve the more data they see, ML algorithms are dynamic and can be retrained with additional and/or different types of labeled data with minimal or no human supervision. For example, the same deep learning algorithms developed for classification of nonclinical images (dogs, cats, trees) have been adapted and reused to detect congenital heart disease, diabetic retinopathy, cardiac views, skin lesions, and a host of other clinical tasks (20,38-40). This is quite important, as an ML algorithm does not need to be fundamentally redesigned when facing a new problem and dataset: the algorithms used to implement a classification task are fundamentally similar whether the data is ECG, ultrasound, or nuclear imaging, the algorithms used to implement a segmentation task are similar whether it is on CT or CMR data, and so forth.

A given neural network can be trained "from scratch" on different datasets for different tasks, or, it can be "pre-trained" on a more general dataset and task to learn very basic data features before being "fine-tuned" on, for example, a cardiology-specific dataset and task (38,40-45). This approach is called transfer learning, and it can be useful when the specialized medical data is rare. Similarly, a model that was trained on a certain cohort of medical data can also be further trained on additional medical data, for example, from another hospital.

Finally, although ML algorithms can be used on different problems with very little tweaking needed, a model trained on a particular data type still has difficulty generalizing knowledge *across* different data types. For example, integrating the information about the left ventricle from multiple data types like an ECG, an echocardiogram, a nuclear study, and a cardiac catheterization is still a task that is much easier for a trained clinician than for an ML model. Such cross-modal synthesis of knowledge from different data types is a task where ML algorithms could have the potential to shine, and this is an active topic of research in computer science.

ML IN CARDIOLOGY: A COMPUTATIONAL SURVEY OF THE LITERATURE AND CASE STUDIES

With a conceptual framework for ML algorithms in place, we now present a survey of the literature on ML in cardiology, highlighting several applications (**Central Illustration**). Because ML papers in cardiology are growing so quickly, we provide an open-source semiautomated method to survey all ML papers in cardiology that can be updated over time, as well as specific case studies to detail several use cases to date: denoising and image enhancement, feature extraction and representation, improving traditional algorithms with data repurposing, novel insights, and improving health care systems.

RESEARCH LANDSCAPE. To provide an informal survey of the research landscape, we retrieved bibliometric information on all publications fitting search terms corresponding to ML and cardiology. These publications were annotated according to whether they were original research or reviews, editorials, or other commentary, as well as according to the ML problem(s) addressed, the ML method(s) used, the cardiology disease(s) studied, and the type(s) of medical data studied. To provide an informal survey of the research landscape, we retrieved bibliometric information on all publications fitting search terms corresponding to machine learning and cardiology. These publications were annotated according to whether they were original research or reviews, editorials, or other commentary; as well as according to the machine learning problem(s) addressed, the machine learning method(s) used, the cardiology disease(s) studied, and the type(s) of medical data studied. These data were retrieved, analyzed, and visualized using the Python programming language and application programming interfaces (APIs) from NCBI PubMed (46) and preprint servers arXiv (47), bioRxiv (48), and medRxiv (49). This approach allowed a method for surveying the literature which can be easily updated and applied toward other search topics. Code is available for use and adaptation by the research community (50). (Figures in the published version of this manuscript use data through July 20, 2020.)

The past 5 years have seen over 3,000 papers on ML in cardiology published in PubMed (about 80% original research) or posted on the popular preprint

TABLE 2 Considerations When Evaluating Machine Learning Manuscripts or Projects

Questions to Ask	Examples
What is the problem being addressed? Is solving the problem impactful for medicine?	*High value:* An unrecognized or unsolved problem; a problem where clinical practice has been shown to fall short. *Intermediate value:* A solution exists, but the new solution provides much better accuracy, reproducibility or time (efficiency) or can work in a different environment or patient group from the current standard. *Low value:* A solution for something that is not a significant clinical problem, or, a robust, well-benchmarked solution already exists.
What is the current state-of-the-art and how does it perform?	Does a highly accurate, scalable, and efficient solution already exist? Is there no good current solution in clinical practice?
Does the problem need a machine learning solution?	Is it a problem of complex pattern finding in complex/nonlinear data? Will the use of machine learning significantly improve the performance with respect to a standard rule-based algorithm?
What benchmark is the machine learning solution trying to beat?	*High clinical impact:* Beating current standard of care (human expertise, prevailing risk prediction model), or no benchmark may exist for an entirely novel model. *Intermediate impact:* A benchmark established by a prior ML model. *Low impact:* Benchmark exists but is not referenced.
If supervised learning is used, what is the ground truth, or gold-standard, label?	*Strong ground-truth label:* A gold-standard diagnosis, such as pathologic diagnosis, as the basis for a disease label. *Intermediate label:* Blinded and/or independent votes from expert clinicians; electronic health record data (depends on the quality of the electronic health record data). *Weak label:* International Classification of Diseases codes alone, or other surrogates that are known to have poor sensitivity and specificity for the condition under study.
If unsupervised learning is used, what methods will be used to validate the patterns learned by the model?	A common example of unsupervised learning is in clustering data into subgroups without a priori knowledge of whether those subgroups are meaningful. In this case, clinically relevant methods of sampling and measuring differences among the learned subgroups are important.
Is the training dataset appropriate for the task at hand?	Classification problems typically need a large amount of training data to avoid overfitting; the only method to verify that the model does not overfit the training data is to verify that the testing set is completely independent from the training set, and that the model performs well in the testing set.
Are the validation and test datasets independent from the training dataset?	Examples of dependent features would include 2 QRS morphologies from 2 electrocardiograms from the same patient, 2 image slices from the same computed tomography scan, or 2 blood glucose measurements from the same patient. Putting one in the training dataset and the other in the test set will make test set performance falsely high. Instead, training and test datasets should be split in a manner that retains sample independence.
Are all datapoints being processed or manipulated in the same manner?	Often, training data needs to be pre-processed to be ready for machine learning. However, it must all be processed in the same way, or else the model runs the risk of learning the manipulations made to one subgroup of data compared to another, rather than learning the meaningful patterns in the data.
How is the clinical use case being formulated?	Whether as a classification problem, a segmentation problem, a time series problem, or something else, the machine learning formulation of the problem should be relevant to the clinical task.
Are methods clear and reproducible?	All information on data preprocessing steps, machine learning algorithms used, and the parameters of those algorithms should be presented. Code can be included, but it must then be tested to run as described.
Are results reported both for the algorithm output and for the clinical problem of interest?	Performance metrics from machine learning algorithms (precision, recall, Dice score, and others) are important. However, results should also be reported in terms clinically relevant to the task (e.g., sensitivity, specificity, number needed to treat, time to diagnosis, and so on). Often, the costs for a false positive or a false negative error are quite different, so it is important to choose a working point that takes into account these different costs. Metrics should include confidence intervals and p values to demonstrate whether they are statistically significantly different from the chosen benchmarks.

servers arXiv and bioRxiv, where scientists are increasingly sharing their papers with each other and with the public before, during, and sometimes as an alternative to, the peer review process (51) (**Figure 1**). This represents tremendous growth, such that in 2020 nearly 1 in every 1,000 new papers in PubMed will be on AI and/or ML in cardiology.

Despite this uptick in publications, there are still several areas that are open for study. For peer-reviewed papers in PubMed, approximately two-thirds involve atherosclerosis (including dyslipidemia and cerebrovascular disease), heart failure, or hypertension and other cardiac risk factors (**Figure 2**). Publications fairly evenly cover the major data types: EHR data, ECG, ultrasound, CMR, and CT. Omics is also a popular subject. The 2 least expensive data types, X-rays and laboratory studies, have received less attention.

The vast majority of publications involving CT looked at atherosclerosis; most heart failure studies

used the EHR and ultrasound; and, predictably, most studies of arrhythmia used ECG data (**Figure 2**). Three-quarters of these papers are about diagnosis, prediction, or classification, with relatively less attention to object tracking and novel biomarker discovery. Consistent with trends across AI and ML, most cardiac AI/ML studies use neural networks (or an ensemble of methods that usually include neural networks), with a minority exclusively using more traditional techniques like linear models, support vector machines, and decision trees.

For papers published in PubMed, the leaders in research output in cardiac AI/ML are the United States (especially California, Massachusetts, and New York) and the United Kingdom, followed by China, Germany, and the Netherlands, with other developed countries contributing materially as well (**Figure 3**). This work is very broadly distributed, with high per-capita contributions from all the developed countries but also work across much of the developing

TABLE 3	Select FDA-Cleared Machine Learning Products for Cardiology	
Company	**Product**	**Indication**
AliveCor	AliveCor Heart Monitor	Atrial fibrillation detection
Apple	Apple Watch	Atrial fibrillation detection
Arterys	CardioDL	CMR measurement
Caption Health	EchoMD AutoEF, Guidance	Echocardiogram LVEF measurement, guidance
Canon	Advanced Intelligent Clear-IQ Engine (AiCE)*	General biomedical image denoising
Eko Devices	Eko Analysis Software	Audiogram interpretation
FitBit	ECG App	Atrial fibrillation detection
PhysIQ	Heart Rhythm and Respiration Module	ECG, vital signs, cardiac function
Qompium	FibriCheck	Atrial fibrillation detection
Shenzhen Carewell Electronics	AI-ECG Platform & Tracker	ECG interpretation
Subtle Medical	SubtlePET,* SubtleMR*	General biomedical image denoising
Ultromics	EchoGo Core	Echocardiogram measurements
Zebra Medical Vision	HealthCCS	Coronary calcium score

*These products are not specifically cardiovascular, but provide general tools for image denoising

CMR = cardiac magnetic resonance imaging; ECG = electrocardiogram; LVEF = left ventricular ejection fraction.

world. Collaborations in cardiac AI/ML span the globe and are similarly multi-institutional within the United States.

CASE STUDIES OF ML IN ACTION. In terms of disease topics and data modalities studied, the survey shows which have been more and less studied. Building from the ML concepts referenced in the previous section, we developed a toolbox of questions and considerations when evaluating the impact and rigor of ML studies (Table 2). With this in mind, we have noted several interesting applications of ML to cardiology. Because of the largely "data-agnostic" nature of ML algorithms (concept 6), we organize these case studies by ML use case, rather than by clinical data type or disease.

Denoising and image enhancement. Across several modalities, ML has been applied to the clinical problem of image post-processing and de-noising. In ultrasound (52,53), CT (54,55), CMR (56,57), and nuclear imaging (58,59), the complex patterns of noise encountered in clinical imaging have lent themselves to neural network-based denoising. In terms of clinical utility, ML has the potential to decrease the time and labor involved in image post-processing and to reduce interoperator, intervendor, and interinstitution differences in data processing. In the case of X-ray and CT imaging, neural network-based image analysis may allow high-quality imaging with reduced radiation dose compared with the current standard. Currently, most ML approaches to denoising have taken a supervised learning approach, where models are being trained to approximate proprietary denoising software as the ground-truth label (53), or are trained by adding noise to input data. Several studies in the literature

have been trained on phantoms and relatively small amounts of clinical data. This means that current neural network denoisers may still be learning relatively simple noise patterns rather than the true extent of variability in clinical imaging. The performance of denoising networks has been primarily measured in terms of comparing input images to their ground-truth labels, which is a necessary and important performance metric; however, measuring changes in diagnostic performance based on machine-learning-based image denoising is an important next step to validating their utility in clinical practice. Some clinical trials are underway to test image denoising on a larger scale (60,61)

Feature extraction and representation. Supervised and unsupervised ML is also being used to represent important features of clinical data into simpler, more compact, more uniform formats: this process is called feature extraction. For example, free-text clinical notes can be analyzed and represented by the list of diseases and procedures mentioned; an ECG can be analyzed and represented by a small group of numbers that summarize the intervals, axis, and QRS morphology; and an ultrasound image can be represented by the structures detected in that image. ML algorithms can also represent data in ways that are not intuitive to a human, but that are nevertheless simpler and more useful to computers. The automatic extraction of these features via complex nonlinear combination of the input data is indeed the key for the superior classification performance of modern deep learning algorithms (21,32). These extracted features can allow for comparing data across institutions (data harmonization), and combining features extracted from different data

types can enable a multimodal representation of a particular patient or disease. Therefore, models that effectively extract important clinical features from different data types in a scalable fashion are fundamentally important to powering larger and more complex ML studies in the near future.

To date, features learned from neural networks and other ML algorithms have been used in cardiology in myriad classification tasks, such as classifying cardiac views from different imaging modalities (20,62) or classifying the presence or absence of disease from image, ECG, text, auscultation, or laboratory data (63-66); segmentation of cardiac structures and/or abnormalities (41,67,68) (**Table 3**); and tissue characterization (69-71) of imaging, text, and ECG data. Several ML algorithms that have been cleared by the U.S. Food and Drug Administration, although proprietary in nature, are likely based on classification and/or segmentation algorithms (examples shown in **Table 3**). Training models to perform these foundational tasks has often required considerable data labeling; therefore, this work will continue to benefit from parallel research on leveraging small datasets (20,72,73) as well as synthesizing larger datasets from smaller ones (74,75).

Improving traditional algorithms and data repurposing for advanced insights. ML is being used to improve upon traditional risk prediction algorithms using available registry data (76-79). ML can enable development of biomarkers that otherwise would be highly labor-intensive to calculate or were not consistently scored on retrospective imaging, such as the quantitation of epicardial adipose tissue on imaging studies to improve risk prediction for myocardial infarction (80); this work is now being studied in a clinical trial (81). Researchers are also using ML to test whether advanced insights are possible from data types not typically used for those insights: examples include using clinical data to predict genetic variants, predicting pulmonary-to-systolic blood flow ratios from chest X-rays, predicting fall risk from wearable home sensors, and calculating a calcium score from chest CTs or from perfusion imaging (45,82-85). These studies benefit when a robust ground-truth label and clinical performance benchmark are present from traditional sources (e.g., genetic sequencing, right heart catheterization, clinical falls data, and standard calcium scores for the examples mentioned here).

Novel insights. In the previous examples, the insights detected can be reasonably expected to be found in the data type studied. For example, even though we use blood chemistry to predict

hyperkalemia precisely, we know that signs of electrolyte imbalance can be evident on ECG. Researchers are using similar approaches to detect novel insight in unexpected data types, finding patterns in data that are not evident to the trained clinician. For example, studies have reported detecting adverse drug reactions from social media, detecting sex from a fundoscopic retinal image, or detecting coronary microvascular resistance from ocular vessel examination (86-88). Especially when initial studies are published from small datasets, there is a possibility that the models are overfitting (Concept 4) rather than finding a true insight. Such findings must be validated rigorously in multicenter datasets and clinical trials, and computational experiments such as saliency and attention mapping must be performed to help understand what data features the ML models are detecting.

Health care systems. Finally, researchers are putting ML to work on systems-level problems in health care, including deployment of AI algorithms for cardiovascular disease screening, and remote monitoring of patient medication adherence and optimization (89-93). The former trial, still underway, studies how AI-derived ECG results to screen for low ejection fraction are delivered to primary care physicians (93). A combination of clinical and administrative data can be used to predict optimal patient scheduling and procedure protocoling, as well as hospital readmission rates, transfer into and out of the intensive care unit, and to reduce false alarms in the intensive care unit (94-97).

These use cases demonstrate how widely ML approaches may change the practice of clinical cardiology. Publications to date still feature largely small and single-center datasets and demonstrate often modest gains over standard-of-care clinical performance; however, the quality and impact of ML in cardiology continues to gain ground, and as these proofs-of-concept mature, we may find them applied to clinical cardiology in the near future.

CHALLENGES AND A CALL TO ACTION FOR CLINICIANS

From our discussion, we see that there is an opportunity for advanced pattern-finding from ML algorithms to help clinicians, especially as medical data is increasing in amount and complexity. We see that in cardiology, ML research is already well underway, with several interesting proofs-of-concept from the research community and some proprietary solutions introduced by industry. We have also seen that

several important concepts in ML research design—including thoughtful selection of use cases and performance metrics, meticulous annotation and curation of datasets, and broad testing and validation to ensure generalizability of results—must be considered and implemented carefully to solve real-world problems in clinical cardiology.

We believe that ML will become part of the clinician's toolbox, at the point of care (in electronic health records and risk calculator algorithms), "under the hood" in diagnostic and therapeutic devices (such as ECG, CT, pacemakers, insulin pumps), and in scheduling and protocolling medical tests and appointments. Although some cardiologists will choose to specialize in ML and data science, cardiologists who are *not* necessarily ML experts also have several important roles to play in the responsible incorporation of ML into cardiology (Table 1), including participating in annotation and curation of data as a clinical expert; advocating for ML solutions that solve important clinical problems for our patients without racial, gender, or other forms of bias; and running rigorous clinical trials of ML algorithms on large patient cohorts. We hope that cardiologists as active participants and informed users will help ensure that ML will live up to its potential to improve the field.

AUTHOR DISCLOSURES

ADDRESS FOR CORRESPONDENCE: Dr. Rima Arnaout, Department of Medicine, Division of Cardiology, Bakar Computational Health Sciences Institute, Center for Intelligent Imaging, Chan Zuckerberg Biohub Intercampus Research Award Investigator, University of California-San Francisco, 555 Mission Bay Boulevard South, San Francisco, California 94158, USA. E-mail: rima.arnaout@ucsf.edu. Twitter: @arnaoutlab, @giorgioquer.

REFERENCES

1. Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP. Machine learning in cardiovascular medicine: are we there yet? Heart 2018;104:1156–64.

2. Standford Medicine. Stanford Medicine 2017 health trends report: harnessing the power of data in health. June 2017. Available at: https://med.stanford.edu/content/dam/sm/sm-news/documents/StanfordMedicineHealthTrendsWhitePaper2017.pdf. Accessed March 20, 2020.

3. Obermeyer Z, Lee TH. Lost in thought - the limits of the human mind and the future of medicine. N Engl J Med 2017;377:1209–11.

4. Litjens G, Ciompi F, Wolterink JM, et al. State-of-the-art deep learning in cardiovascular image analysis. J Am Coll Cardiol Img 2019;12:1549–65.

5. Sardar P, Abbott JD, Kundu A, Aronow HD, Granada JF, Giri J. Impact of artificial intelligence on interventional cardiology: from decision-making aid to advanced interventional procedure assistance. J Am Coll Cardiol Intv 2019;12:1293–303.

6. Sengupta PP. Intelligent platforms for disease assessment: novel approaches in functional echocardiography. J Am Coll Cardiol Img 2013;6:1206–11.

7. Dey D, Slomka PJ, Leeson P, et al. Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:1317–35.

8. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med 2019;380:1347–58.

9. Nicol ED, Norgaard BL, Blanke P, et al. The Future of cardiovascular computed tomography: advanced analytics and clinical insights. J Am Coll Cardiol Img 2019;12:1058–72.

10. Chang A. Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare. 1st Edition. Cambridge, MA: Academic Press, 2020.

11. Norgeot B, Quer G, Beaulieu-Jones BK, et al. Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist. Nat Med 2020;26:1320–4.

12. Kossmann CE. Electrocardiographic Analysis by Computer. JAMA 1965;191:922–4.

13. Smulyan H. The computerized ECG: friend and foe. Am J Med 2019;132:153–60.

14. Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med 2019;25:70–4.

15. Porumb M, Stranges S, Pescapè A, Pecchia L. Precision medicine and artificial intelligence: a pilot study on deep learning for hypoglycemic events detection based on ECG. Sci Rep 2020;10:170.

16. Henglin M, Stein G, Hushcha PV, Snoek J, Wiltschko AB, Cheng S. Machine learning approaches in cardiovascular imaging. Circ Cardiovasc Imaging 2017;10:e005614.

17. Deo RC. Machine learning in medicine. Circulation 2015;132:1920–30.

18. Sengupta PP, Shrestha S, Berthon B, et al. Proposed requirements for cardiovascular imaging-related machine learning evaluation (PRIME): a checklist: reviewed by the American College of Cardiology Healthcare Innovation Council. J Am Coll Cardiol Img 2020;13:2017–35.

19. Hannun AY, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med 2019;25:65–9.

20. Madani A, Arnaout R, Mofrad M. Fast and accurate view classification of echocardiograms using deep learning. NPJ Digit Med 2018;1:6.

21. Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet 2019;394:861–7.

22. Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE Study. Med Care 2017;55:e137–43.

23. Johnson KW, Torres Soto J, Glicksberg BS, et al. Artificial intelligence in cardiology. J Am Coll Cardiol 2018;71:2668–79.

24. Miotto R, Li L, Kidd BA, Dudley JT. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Sci Rep 2016;6:26094.

25. Li L, Cheng WY, Glicksberg BS, et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med 2015;7:311ra174.

26. Shomorony I, Cirulli ET, Huang L, et al. An unsupervised learning approach to identify novel signatures of health and disease from multimodal data. Genome Med 2020;12:7.

27. Luo Y, Ahmad FS, Shah SJ. Tensor factorization for precision medicine in heart failure with preserved ejection fraction. J Cardiovasc Transl Res 2017;10:305–12.

28. Katz DH, Deo RC, Aguilar FG, et al. Phenomapping for the identification of hypertensive patients with the myocardial substrate for heart failure with preserved ejection fraction. J Cardiovasc Transl Res 2017;10:275–84.

29. Yu C, Liu J, Zhao H. Inverse reinforcement learning for intelligent mechanical ventilation and sedative dosing in intensive care units. BMC Med Inform Decis Mak 2019;19:57.

30. Levy AE, Biswas M, Weber R, et al. Applications of machine learning in decision analysis for dose management for dofetilide. PLoS One 2019; 14:e0227324.

31. Zech JR, Badgeley MA, Liu M, Costa AB, Titano JJ, Oermann EK. Variable generalization performance of a deep learning model to detect pneumonia in chest radiographs: A cross-sectional study. PLoS Med 2018;15:e1002683.

32. Gadaleta M, Rossi M, Topol EJ, Steinhubl SR, Quer G. On the effectiveness of deep representation learning: the atrial fibrillation case. Computer (Long Beach Calif) 2019;52:18–29.

33. Elite Data Science. Overfitting in machine learning: what it is and how to prevent it. Available at: http://elitedatascience.com/overfitting-in-machine-learning. Accessed March 30, 2020.

34. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nature Machine Intelligence 2019;1:206–15.

35. Topol EJ. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human again. First edition. New York: Basic Books, 2019.

36. Molnar C. Interpretable machine learning. A guide for making black box models explainable. 2019. Available at: https://christophm.github.io/interpretable-ml-book/. Accessed March 29, 2020.

37. Marcus G. The next decade in AI: four steps towards robust artificial intelligence. arXiv e-prints, 2020. arXiv 200206177.

38. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017;542:115–8.

39. Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 2016;316:2402–10.

40. Arnaout R, Curran L, Zhao Y, Levine J, Chinn E, Moon-Grady A. Expert-level prenatal detection of complex congenital heart disease from screening ultrasound using deep learning. medRxiv 2020. 2020.06.22.20137786.

41. Chen HH, Liu CM, Chang SL, et al. Automated extraction of left atrial volumes from two-dimensional computer tomography images using a deep learning technique. Int J Cardiol 2020;316: 272–8.

42. Gessert N, Lutz M, Heyder M, et al. Automatic plaque detection in IVOCT pullbacks using convolutional neural networks. IEEE Trans Med Imaging 2019;38:426–34.

43. Matsumoto T, Kodera S, Shinohara H, et al. Diagnosing heart failure from chest x-ray images using deep learning. Int Heart J 2020;61:781–6.

44. Tadesse GA, Zhu T, Liu Y, et al. Cardiovascular disease diagnosis using cross-domain transfer learning. Conf Proc IEEE Eng Med Biol Soc 2019; 2019:4262–5.

45. Toba S, Mitani Y, Yodoya N, et al. Prediction of pulmonary to systemic flow ratio in patients with congenital heart disease using deep learning-based analysis of chest radiographs. JAMA Cardiol 2020;5:449–57.

46. Pubmed. Available at: https://www.ncbi.nlm.nih.gov/pubmed/. Accessed September 20, 2020.

47. arXiv.org. Available at: https://arxiv.org/. Accessed September 20, 2020.

48. bioRxiv: The preprint server for biology. Available at: https://biorxiv.org. Accessed September 20, 2020.

49. medRxiv: The preprint server for health sciences. Available at: https://medrxiv.org. Accessed September 20, 2020.

50. ArnaoutLabUCSF/cardioML. Available at: https://github.com/ArnaoutLabUCSF/cardioML/tree/master/JACC_2021/. Accessed December 27, 2020.

51. Abdill RJ, Blekhman R. Tracking the popularity and outcomes of all bioRxiv preprints. Elife 2019; 8:e45133.

52. Diller GP, Lammers AE, Babu-Narayan S, et al. Denoising and artefact removal for transthoracic echocardiographic imaging in congenital heart disease: utility of diagnosis specific deep learning algorithms. Int J Cardiovasc Imaging 2019;35:2189–96.

53. Huang O, Long W, Bottenus N, et al. MimickNet, mimicking clinical image post-processing under black-box constraints. IEEE Trans Med Imaging 2020;39:2277–86.

54. Blendowski M, Bouteldja N, Heinrich MP. Multimodal 3D medical image registration guided by shape encoder-decoder networks. Int J Comput Assist Radiol Surg 2020;15:269–76.

55. Benz DC, Benetos G, Rampidis G, et al. Validation of deep-learning image reconstruction for coronary computed tomography angiography: impact on noise, image quality and diagnostic accuracy. J Cardiovasc Comput Tomogr 2020;14:444–51.

56. Qin C, Schlemper J, Caballero J, Price AN, Hajnal JV, Rueckert D. Convolutional recurrent neural networks for dynamic MR image reconstruction. IEEE Trans Med Imaging 2019;38: 280–90.

57. Küstner T, Armanious K, Yang J, Yang B, Schick F, Gatidis S. Retrospective correction of motion-affected MR images using deep learning frameworks. Magn Reson Med 2019;82:1527–40.

58. Doris MK, Otaki Y, Krishnan SK, et al. Optimization of reconstruction and quantification of motion-corrected coronary PET-CT. J Nucl Cardiol 2020;27:494–504.

59. Lassen ML, Beyer T, Berger A, et al. Data-driven, projection-based respiratory motion compensation of PET data for cardiac PET/CT and PET/MR imaging. J Nucl Cardiol 2019 Feb 13 [E-pub ahead of print].

60. Johns Hopkins University, Canon Medical Systems. Comparison of Magnetic Resonance Coronary Angiography (MRCA) With Coronary Computed Tomography Angiography (CTA); 2021. Available at: https://ClinicalTrials.gov/show/NCT03768999. Accessed September 20, 2020.

61. University of Zurich. Deep-Learning Image Reconstruction in CCTA; 2019. Available at: https://ClinicalTrials.gov/show/NCT03980470. Accessed September 20, 2020.

62. Ostvik A, Smistad E, Aase SA, Haugen BO, Lovstakken L. Real-time standard view classification in transthoracic echocardiography using convolutional neural networks. Ultrasound Med Biol 2019;45:374–84.

63. Fries JA, Varma P, Chen VS, et al. Weakly supervised classification of aortic valve malformations using unlabeled cardiac MRI sequences. Nat Commun 2019;10:3111.

64. Papworth Hospital, N.H.S. Foundation Trust. To assess specificity of an algorithm for detecting clinically significant valve disease and congenital heart disease relative to the performance of General Practitioners; 2021. Available at: https://ClinicalTrials.gov/show/NCT04445012. Accessed September 20, 2020.

65. Eko Devices, Inc. Heart Failure Monitoring With Eko Electronic Stethoscopes; 2021. Available at: https://ClinicalTrials.gov/show/NCT04404452. Accessed September 20, 2020.

66. Akron Children's H, Dispenza TC, Bockoven JR. The Accuracy of an Artificially-intelligent Stethoscope. Available at: https://ClinicalTrials.gov/show/NCT00564122. Accessed September 20, 2020.

67. Leclerc S, Smistad E, Pedrosa J, et al. Deep learning for segmentation using an open large-scale dataset in 2D echocardiography. IEEE Trans Med Imaging 2019;38:2198–210.

68. Du X, Yin S, Tang R, Zhang Y, Li S. Cardiac-DeepIED: automatic pixel-level deep segmentation for cardiac bi-ventricle using improved end-to-end encoder-decoder network. IEEE J Transl Eng Health Med 2019;7:1900110.

69. Cilla M, Pérez-Rey I, Martínez MA, Peña E, Martínez J. On the use of machine learning techniques for the mechanical characterization of soft biological tissues. Int J Numer Method Biomed Eng 2018;34:e3121.

70. Lee J, Prabhu D, Kolluru C, et al. Fully automated plaque characterization in intravascular OCT images using hybrid convolutional and lumen morphology features. Sci Rep 2020;10:2596.

71. Pazinato DV, Stein BV, de Almeida WR, et al. Pixel-level tissue classification for ultrasound images. IEEE J Biomed Health Inform 2016;20: 256–67.

72. Wong KCL, Syeda-Mahmood T, Moradi M. Building medical image classifiers with very limited data using segmentation networks. Med Image Anal 2018;49:105–16.

73. Guo F, Ng M, Goubran M, et al. Improving cardiac MRI convolutional neural network segmentation on small training datasets and dataset shift: a continuous kernel cut approach. Med Image Anal 2020;61:101636.

74. Duchateau N, Sermesant M, Delingette H, Ayache N. Model-based generation of large databases of cardiac images: synthesis of pathological cine MR sequences from real healthy cases. IEEE Trans Med Imaging 2018;37:755–66.

75. Beaulieu-Jones BK, Wu ZS, Williams C, et al. Privacy-preserving generative deep neural networks support clinical data sharing. Circ Cardiovasc Qual Outcomes 2019;12:e005122.

76. Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC / AHA CVD risk calculator in MESA. J Am Heart Assoc 2018;7:e009476.

77. Al'Aref SJ, Maliakal G, Singh G, et al. Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography: analysis from the CONFIRM registry. Eur Heart J 2020;41:359–67.

78. Myers PD, Huang W, Anderson F, Stultz CM. Choosing clinical variables for risk stratification post-acute coronary syndrome. Sci Rep 2019;9: 14631.

79. Tokodi M, Schwertner WR, Kovács A, et al. Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score. Eur Heart J 2020;41:1747–56.

80. Eisenberg E, McElhinney PA, Commandeur F, et al. Deep learning-based quantification of epicardial adipose tissue volume and attenuation predicts major adverse cardiovascular events in

asymptomatic subjects. Circ Cardiovasc Imaging 2020;13:e009829.

81. Commandeur F, Slomka PJ, Goeller M, et al. Machine learning to predict the long-term risk of myocardial infarction and cardiac death based on clinical risk, coronary calcium, and epicardial adipose tissue: a prospective study. Cardiovasc Res 2019 Dec 19 [E-pub ahead of print].

82. Yang Y, Hirdes JP, Dubin JA, Lee J. Fall risk classification in community-dwelling older adults using a smart wrist-worn device and the resident assessment instrument-home care: prospective observational study. JMIR Aging 2019;2:e12153.

83. Pina A, Helgadottir S, Mancina RM, et al. Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. Eur J Prev Cardiol 2020:2047487319898951.

84. van Velzen SGM, Lessmann N, Velthuis BK, et al. Deep learning for automatic calcium scoring in CT: validation using multiple cardiac CT and chest CT protocols. Radiology 2020;295:66–79.

85. Dekker M, Waissi F, Bank IEM, et al. Automated calcium scores collected during myocardial perfusion imaging improve identification of obstructive coronary artery disease. Int J Cardiol Heart Vasc 2020;26:100434.

86. Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. Nat Biomed Eng 2018;2:158–64.

87. Rezaei Z, Ebrahimpour-Komleh H, Eslami B, Chavoshinejad R, Totonchi M. Adverse drug reaction detection in social media by deep learning methods. Cell J 2020;22:319–24.

88. Hospices Civils de Lyon. Can we Predict COronary Resistance By EYE Examination? (COREYE); 2020. Available at: https://ClinicalTrials.gov/show/NCT03739073. Accessed September 20, 2020.

89. Optima Integrated, Health and University of California, San Francisco. Tailored Drug Titration Using Artificial Intelligence; 2021. Available at: https://ClinicalTrials.gov/show/NCT04223934. Accessed September 20, 2020.

90. AiCure, Montefiore Medical Center. Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy; 2016. Available at: https://ClinicalTrials.gov/show/NCT02599259. Accessed September 20, 2020.

91. University of, Michigan, Agency for Healthcare, Research and Quality. Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages; 2016. Available at: https://ClinicalTrials.gov/show/NCT02454660. Accessed September 20, 2020.

92. Optima Integrated, Health and University of California, San Francisco. Piloting Healthcare Coordination in Hypertension; 2017. Available at: https://ClinicalTrials.gov/show/NCT02988193. Accessed September 20, 2020.

93. Yao X, McCoy RG, Friedman PA, et al. ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial. Am Heart J 2020;219: 31–6.

94. Carlin CS, Ho LV, Ledbetter DR, Aczon MD, Wetzel RC. Predicting individual physiologically acceptable states at discharge from a pediatric intensive care unit. J Am Med Inform Assoc 2018; 25:1600–7.

95. Chu J, Dong W, He K, Duan H, Huang Z. Using neural attention networks to detect adverse medical events from electronic health records. J Biomed Inform 2018;87:118–30.

96. Hever G, Cohen L, O'Connor MF, Matot I, Lerner B, Bitan Y. Machine learning applied to multi-sensor information to reduce false alarm rate in the ICU. J Clin Monit Comput 2020;34: 339–52.

97. Au-Yeung WM, Sahani AK, Isselbacher EM, Armoundas AA. Reduction of false alarms in the intensive care unit using an optimized machine learning based approach. NPJ Digit Med 2019;2:86.